Search company, investor...

Critical Biologics

criticalbiologics.com

Founded Year

2004

Stage

Debt | Alive

Total Raised

$9.81M

Last Raised

$500K | 14 yrs ago

About Critical Biologics

Critical Biologics Corporation (CBC), based in Cambridge, MA, is a small biotechnology company committed to making available products to address the many unmet medical needs in Critical Care Medicine. The company believe that the traditional commercial approach of targeting a single facet of a therapydrug, device, diagnostic, or monitor ignores the fact that often these modalities are employed together by Intensivists to treat the increasing complex diseases of their patients.

Headquarters Location

One Mifflin Place Suite 400

Cambridge, Massachusetts, 02138,

United States

908-439-9768

Missing: Critical Biologics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Critical Biologics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Critical Biologics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Critical Biologics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Critical Biologics Frequently Asked Questions (FAQ)

  • When was Critical Biologics founded?

    Critical Biologics was founded in 2004.

  • Where is Critical Biologics's headquarters?

    Critical Biologics's headquarters is located at One Mifflin Place, Cambridge.

  • What is Critical Biologics's latest funding round?

    Critical Biologics's latest funding round is Debt.

  • How much did Critical Biologics raise?

    Critical Biologics raised a total of $9.81M.

  • Who are the investors of Critical Biologics?

    Investors of Critical Biologics include Morningside Ventures.

  • Who are Critical Biologics's competitors?

    Competitors of Critical Biologics include Bone Biologics, Apitope, ViroPharma, Genolyze Oy, Quantum Immunologics and 11 more.

Compare Critical Biologics to Competitors

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

J
J. Lamarck

J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.

K
Kryosphere

Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.

A
Algae Biosciences

Algae Biosciences Corporation ("AlgaeBio") is a biotechnology company that aims to produce ultra-pure products from microalgae and macroalgae in a facility located near Holbrook, Arizona. The company has been producing microalgae on a small scale since October 2006. It aims to offer, per the company, the tools for harnessing the potential of the most prolific, abundant resource on the company's planet: the 200,000-plus known species of algae. Each species aims to offer downstream product potentials.

A
Argolyn Bioscience

Argolyn Bioscience is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Its most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia.

P
ProtAffin

ProtAffin is a pre-clinical biotechnology company developing protein-based products countering inflammation. Its biologics targets the heparin-like glycan structures that drive inflammatory processes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.